A phase 1 trial of ALXN1210.
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 16 Feb 2017
At a glance
- Drugs Ravulizumab (Primary)
- Indications Immunological disorders
- Focus Adverse reactions
- Sponsors Alexion Pharmaceuticals
- 16 Feb 2017 Status changed from recruiting to active, no longer recruiting, as reported in an Alexion Pharmaceuticals media release.
- 27 Oct 2016 According to an Alexion Pharmaceuticals media release, company started dosing new formulation of ALXN1210 in this study.
- 02 Feb 2015 New trial record